Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Frank Buck who wrote (1514)	3/10/1998 2:35:00 PM
From: Sigmund	Read Replies (1) \| Respond to of 1894

Smith Klein Beecham is NeoPath's major customer for secondary screening and has been mentioned as a possible acquirer down the road of NeoPath. They may want to make NeoPath viable. I have no special information on this but it is the only thing positive that I can see happening to NeoPath in the short run. Yes it is good that ACMIC has finally sought professional assistance in planning their future. If they had done that last September we probably would be at $3 now rather than $3/4. I don't know if an investment banker will be able to move by March 20 so that is a problem. Longer term I think it is very favorable. I think it relates to more than what you have mentioned but I have no way of knowing. The short term problem is that sometimes existing shareholders get the short end of the stick in order to attract new money. In the long run all will benefit but I am not sure how this will work out in the short run. It is now Tuesday and no sign of anything happening. That doesn't make me very comfortable.